Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Corcept Therapeutics (CORT) Interest & Investment Income (2016 - 2019)

Corcept Therapeutics (CORT) has disclosed Interest & Investment Income for 5 consecutive years, with $1.1 million as the latest value for Q1 2019.

  • For Q1 2019, Interest & Investment Income rose 273.13% year-over-year to $1.1 million; the TTM value through Mar 2019 reached $3.5 million, up 636.17%, while the annual FY2022 figure was $3.6 million, 572.4% up from the prior year.
  • Interest & Investment Income hit $1.1 million in Q1 2019 for Corcept Therapeutics, up from $1.0 million in the prior quarter.
  • Across five years, Interest & Investment Income topped out at $1.1 million in Q1 2019 and bottomed at -$487000.0 in Q3 2016.
  • Average Interest & Investment Income over 4 years is $255272.7, with a median of $188000.0 recorded in 2017.
  • Year-over-year, Interest & Investment Income surged 117.66% in 2017 and then surged 782.56% in 2018.
  • Corcept Therapeutics' Interest & Investment Income stood at -$410000.0 in 2016, then skyrocketed by 145.85% to $188000.0 in 2017, then soared by 454.26% to $1.0 million in 2018, then rose by 5.28% to $1.1 million in 2019.
  • According to Business Quant data, Interest & Investment Income over the past three periods came in at $1.1 million, $1.0 million, and $759000.0 for Q1 2019, Q4 2018, and Q3 2018 respectively.